Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
Trial ID or NCT#
NCT02785250
Status
NOT RECRUITING
Purpose
T cell activating therapy DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the safety and potential immune-modulating activity of the combination of these agents.
Official Title
A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer
Investigator(s)
Oliver Dorigo, M.D., Ph.D.
Gynecologic oncologist,
Medical oncologist,
Gynecologic oncologist
Mary Lake Polan Professor
Amer Karam
Gynecologic oncologist
Clinical Professor, Obstetrics & Gynecology - Gynecologic Oncology
Contact us to find out if this trial is right for you.
Contact
Alma Gonzalez
650-498-0624
View on ClinicalTrials.gov
